MG
IOVA icon

Mather Group’s Iovance Biotherapeutics IOVA Stock Holding History

Mather Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-133
Closed -$1.97K – 1946
2024
Q2 		$1.97K Buy
+133
New +$1.43K ﹤0.01% 1890

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Mather Group's IOVA Position: Q3 2024 in Review

Mather Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2024, closing a stake of 133 shares — an estimated $1.97K sold.

Mather Group first reported a position in IOVA in Q2 2024 and held it in 1 quarter. The position peaked at $1.97K in Q2 2024. 286 funds tracked by Wall St. Rank hold IOVA as of Q3 2024.

  • Mather Group reported no remaining Iovance Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • Mather Group sold 133 Iovance Biotherapeutics shares in Q3 2024, an estimated $1.97K.
  • Mather Group first reported a position in Iovance Biotherapeutics in Q2 2024 and held it in 1 quarter.
  • Mather Group's Iovance Biotherapeutics position peaked at $1.97K in Q2 2024.
  • 286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.